A 68-year-old woman was initially admitted with 2 subannular pseudoaneurysms of the aortic root after aortic valve replacement. The aneurysm expanded after 10 days and was treated using endovascular closure devices. ( Level of Difficulty: Advanced. )
<p><strong>Background. </strong>Chronically occluded coronary arteries (CTO) are a common finding in coronary angiography. The technical success rate of endovascular recanalisation of CTO is high; however, the effect of technical success on long-term clinical results remains unclear.<strong></strong></p><p><strong>Aim. </strong>To evaluate long-term outcomes of CTO recanalisation according to technical success of the procedure.<strong></strong></p><p><strong>Methods. </strong>We evaluated 1073 patients who underwent endovascular recanalisation of CTO from 2013 to 2019. Assessment of clinical results was performed via phone call or follow-up visit at years 1, 2, 3, 4 and 5. Survival was evaluated using the Kaplan–Meier method and compared between the technical success and technical failure groups using the log-rank test. The initial clinical and angiographic characteristics and procedural results of recanalisation were included as probable predictors of adverse cardiovascular events in uni- and multivariate regression analyses.</p><p><strong>Results. </strong>Mean follow-up was 2.7 ± 1.9 years. The incidence of adverse cardiovascular events, including death from all causes, nonfatal myocardial infarction, stroke and unplanned myocardial revascularisation was 11.4% in the technical success group and 24% in the technical failure group (p = 0.0001). The difference was mainly due to the higher prevalence of repeat revascularisation in the technical failure group (6.7% vs. 18.1%, p = 0.0001). Differences in mortality (2.7% vs. 3.8%, p = 0.38), stroke (0.6% vs. 0.4%, p = 0.99) and myocardial infarction (2% vs. 4%, p = 0.13) were not observed. Multivariate regression analysis found that ejection fraction of the left ventricle, calcification of the coronary arteries and technical success were independent predictors of adverse events.</p><p><strong>Conclusion. </strong>Successful recanalisation of CTO is associated with fewer adverse cardiovascular events over the long term. Technical failure, calcification and low ejection fraction are independent predictors of adverse events.</p><p>Received 10 June 2020. Revised 10 July 2020. Accepted 13 July 2020.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions<br /></strong>Conception and design: O.V. Krestyaninov, A.M. Chernyavskiy<br />Data collection and analysis: O.V. Krestyaninov, D.A. Khelimskii, A.G. Badoian<br />Statistical analysis: D.N. Ponomarev, A.G. Badoian, D.A. Khelimskii<br />Drafting the article: O.V. Krestyaninov, D.A. Khelimskii, K.A. Rzaeva<br />Critical revision of the article: O.V. Krestyaninov, A.M. Chernyavskiy<br />Final approval of the version to be published: O.V. Krestyaninov, D.A. Khelimskii, A.G. Badoian, K.A. Rzaeva, D.N. Ponomarev, A.M. Chernyavskiy</p>
Over the past 40 years, various types of prostheses have been developed for right ventricular outflow tract reconstruction. However, conduit stenosis and insufficiency due to valve degeneration occur frequently, decreasing the lifetime of patients. Transcatheter stenting of conduits does not always give favorable results and can lead to severe pulmonary regurgitation. The novel method of percutaneous pulmonary valve implantation is a good alternative to the surgical intervention according to data on long-term survival and quality of life.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.